Korio has filed a notice of an exempt offering of securities to raise $5,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Korio is raising up to $5,500,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Ryan Keane played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Korio
Korio is the Randomization & Trial Supply Management (RTSM) platform designed for flexibility, quality and speed. Not just built to tackle clinical trial challenges as they come, but built to prevent them in the first place. No matter what trials you may face, Korio is prepared to handle them.
To learn more about Korio, visit http://www.korioclinical.com/
Korio Linkedin Page: https://www.linkedin.com/company/korio-inc/
Contact:
Ryan Keane, President and Chief Executive Officer
415-531-5917
https://www.linkedin.com/in/ryan-keane-2293ba1/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.